HaystackAnalytics develops UID genomic test

HaystackAnalytics, a Mumbai-based health-tech startup, has developed the first of its kind Universal Infectious Diseases (UID) Test in the country, that deploys Next-Generation Sequencing (NGS) technology to identify existing and emerging infections, while providing information on drug resistance to support and identify correct treatment options for patients. HaystackAnalytics has partnered with various diagnostic centers such as Unipath, Anderson, Sterling Accuris, Apollo Hospitals and over 20+ hospitals including AIIMS, to introduce their Sequencing based clinical products for TB and COVID-19 in the past. The new Universal Infectious Diseases test developed by HaystackAnalytics will be rolled out with their current partners in a phased manner over the next three months, and will be initially targeted at identifying and treating sepsis in Intensive Care Unit (ICU) patients, but gradually be made available to anyone suffering from a fever of unknown origin, by eradicating the need to conduct multiple tests.